Phlow Corp., a U.S.-based essential medicines impact company, has been approved for inclusion in the Biomedical Advanced Research and Development Authority (BARDA) contract development and manufacturing organization (CDMO) network. The network is part of a comprehensive effort by the U.S. government to provide a domestically integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools to address public health emergencies.
 
BARDA, which is part of the office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), is working to proactively address threats to the health of the U.S. population. Central to this mission, BARDA’s CDMO network includes highly vetted manufacturers that are prequalified and ready to immediately deliver key medicines to help ensure the health of all Americans.
 
“Phlow is honored to be included in the BARDA CDMO network as part of a shared commitment to securing our nation with a predictable and stable domestic supply of essential medicines,” said Eric Edwards, president, co-founder and CEO of Phlow. “Together with the U.S. government, we will ensure preparedness for future national health crises with an integrated, cost-effective, and comprehensive solution that provides reliability, high quality, and supply chain resilience.”
 
Phlow is currently working with BARDA to operationalize a U.S.-based essential medicines supply chain solution. Through a partnership with HHS/ASPR/BARDA, Phlow is actively developing active pharmaceutical ingredients (APIs) by leveraging state-of-the-art green chemistry, continuous flow technology, and other advanced manufacturing processes to improve the development and manufacturing of APIs and finished pharmaceutical products critical to U.S. healthcare while reducing the nation’s reliance on imports from foreign nations.